Sulfonamide derivative or pharmaceutically acceptable acid-addition salt
The present invention aims to provide a novel low-molecular-weight compound showing an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.
1. A compound represented by the formula
wherein R is propyl, ethyl, isopropyl, methoxy or ethoxy, and Me is methyl,
or a pharmaceutically acceptable acid addition salt thereof.
2. The compound according to claim 1
which is 4′-methoxy-N,N-dimethyl-3′-(N-(3-(2-oxo-3-(4-propylphenyl)tetrahydropyrimidin-1(2H)-yl) phenyl)sulfamoyl)-[1,1′-biphenyl]-3-carboxamide or 4′-(methoxy-d3)-N, N-dimethyl-3′-(N-(3-(2-oxo-3-(4-propylphenyl)tetrahydropyrimidin-1(2H)-yl) phenyl)sulfamoyl)-[1,1′-biphenyl]-3-carboxamide, or a pharmaceutically acceptable acid addition salt thereof.
3. The compound according to claim 1 which is 4′ -methoxy-N,N-dimethyl-3′-(N-(3-(2-oxo-3-(4-propylphenyl)tetrahydropyrimidin-1 (2H)-yl)phenyl)sulfamoyl)-[1,1′-biphenyl]-3-carboxamide or a pharmaceutically acceptable acid addition salt thereof.
4. The compound according to claim 1 which is 4′-(methoxy-d3)-N,N-dimethyl-3′-(N-(3-(2-oxo-3-(4-propylphenyl) tetrahydropyrimidin-1(2H)-yl)phenyl)sulfamoyl)-[1,1′-biphenyl]-3-carboxamide or a pharmaceutically acceptable acid addition salt thereof.
5. A medicament comprising the compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.
6. An orexin receptor agonist comprising the compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.
7. An anti-narcolepsy agent comprising the compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.
8. An agent for improving sleepiness comprising the compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.
9. A therapeutic agent for obesity, diabetes or depression comprising the compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.
10. A method of treating narcolepsy comprising administering an effective amount of the compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.
11. A method of improving sleepiness comprising administering an effective amount of the compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.
12. A method of treating obesity, diabetes or depression comprising administering an effective amount of the compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.
13. A medicament comprising the compound according to claim 2 or a pharmaceutically acceptable acid addition salt thereof.
14. A method of treating narcolepsy comprising administering an effective amount of the compound according to claim 2 or a pharmaceutically acceptable acid addition salt thereof.
15. A method of improving sleepiness comprising administering an effective amount of the compound according to claim 2 or a pharmaceutically acceptable acid addition salt thereof.
16. A method of treating obesity, diabetes or depression comprising administering an effective amount of the compound according to claim 2 or a pharmaceutically acceptable acid addition salt thereof.